Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20495207 | 0.84 | HDAC11 (0.45) | MAPTSIGMAR1HDAC11BTK | |
| SCHEMBL20494367 | 0.84 | HDAC11 (0.45) | MAPTSIGMAR1HDAC11BTK | |
| SCHEMBL20495223 | 0.84 | HDAC11 (0.45) | MAPTSIGMAR1HDAC11BTK | |
| SCHEMBL23326734 | 0.84 | HDAC11 (0.45) | MAPTSIGMAR1HDAC11BTK | |
| SCHEMBL14256288 | 0.82 | CCR3 (0.45) | MAPTSIGMAR1HDAC11GBA1 | |
| SCHEMBL20494596 | 0.81 | MAPT (0.43) | MAPTSIGMAR1HDAC11BTKGBA1 | |
| SCHEMBL9697554 | 0.80 | SIGMAR1 (0.43) | MAPTSIGMAR1HDAC11GBA1DRD2 | |
| SCHEMBL9696934 | 0.80 | SIGMAR1 (0.43) | MAPTSIGMAR1HDAC11GBA1DRD2 | |
| SCHEMBL23326928 | 0.79 | HDAC11 (0.41) | MAPTSIGMAR1HDAC11BTK | |
| SCHEMBL25339102 | 0.79 | NR1H2 (0.50) | SIGMAR1HDAC11BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938114-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938114-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | MAPT 4395/4885SIGMAR1 1147/4885HDAC11 2222/4885 |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | MAPT 4395/4885SIGMAR1 1147/4885HDAC11 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.